Stock Ratings / Health Care / MGTX / forecast

GLUE (33) PRME (21) ODTX (59) CGEM (36) ⌘ Pro Terminal →

MeiraGTx Holdings plc (MGTX) 12-Month Stock Forecast & Price Target Cone

Q: Is MGTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, MeiraGTx Holdings plc (NASDAQ: MGTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $9.71 (-0.46% 1D, market cap $932.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MGTX ranks #974 in composite RQD confidence.

Q: How does MGTX compare to GLUE and PRME in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MGTX carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GLUE (Monte Rosa Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $927.4M) and PRME (Prime Medicine Inc.) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $950.4M). Among the 5-stock peer group, MGTX leads on earnings multiple (N/A) while MGTX leads on capital efficiency (-35.0% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for MGTX?

Per MGTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001735438), MeiraGTx Holdings plc generated $81.4M in revenue (+144.6% YoY), $0 in net income, and -$50.2M in free cash flow against $244.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is MGTX trading relative to its 50-day, 200-day, and 52-week technical levels?

MGTX last traded at $9.71 (-0.46% on volume of 499,196 shares), positioning the stock -17.08% below its 50-day simple moving average ($11.71) and -5.82% below its 200-day simple moving average ($10.31). Across its 52-week range of $6.62 to $15.35, MGTX sits at the 35.4% percentile with a 14-day RSI of 38.3 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($8.62 to $10.80).

Q: What is MGTX's 12-month stock price target?

MeiraGTx Holdings plc (MGTX) carries a 12-month consensus base price target of $8.36 (-13.9% from $9.71), with a bull-case target of $16.12 and a bear-case floor of $6.52.

Q: Is MGTX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates MGTX E (Strong Sell — SELL) with an RQD Confidence score of 27/100.

$9.71 -0.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.68

MeiraGTx Holdings plc (MGTX) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $932.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.68 (-0.27%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MGTX)Realized 20D OHLCV Swing Band: ±11.2%

Deterministic 5-Pillar Attribution (27/100 Composite)

🔍 WHY MGTX SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (30% of score)

20D Institutional Volume Accumulation (±11.2% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (26% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$10.69-13.2% Next Q

Q2 (-2Q)

Grade E$9.28-0.8% Next Q

Q3 (-1Q)

Grade E$9.21+5.4% Next Q

Current

Grade E$9.71-10.3% Hist 90D α

Trajectory: E (35) → E (27)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MGTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MGTX currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.71) and Max Pain ($10.20) forces dealer call-delta covering toward $16.12.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MGTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MGTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 27%NO 73%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your MGTX Position Size: $10,000

Shares at $9.71: 1029.9 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $6.52

$6,715

$-3,285 (-32.9%)

12M Consensus BaseTarget $8.36

$8,610

$-1,390 (-13.9%)

12M Bull Case BreakoutTarget $16.12

$16,601

+$6,601 (+66.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$9	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$15	69%	B
JP MorganUS Large-Cap Research	SELL	$7	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MGTX)

✓Walkthrough of MGTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MGTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +5.31%📐 HORIZONTAL RANGE

2026-10-30O $9.65H $9.71L $9.30C $9.71VOL 452.2K

RES: $15.26SUP: $8.90SMA50: $11.71SMA200: $10.31

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MGTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MGTX Butterfly Map → + Track MGTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +144.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MGTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MGTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MGTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MGTX)

Health Care Rank #974 of 1016 ⚔️ GLUE vs MGTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MGTX vs. GLUE, PRME, ODTX, CGEM)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, MeiraGTx Holdings plc (MGTX) ranks #974 by composite RQD confidence (27/100, grade E) and #370 by equity capitalization ($932.1M). Within this direct 5-issuer industry benchmark cohort, MGTX leads on earnings valuation at N/A trailing P/E, while MGTX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with MGTX at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MGTX ACTIVE MeiraGTx Holdings plc	E	27/100	—	—	-35.0%	-0.46%	$932.1M	Benchmark Subject
GLUE Monte Rosa Therapeutics Inc.	E	33/100	—	—	-35.0%	+0.18%	$927.4M	/glue-vs-mgtx →
PRME Prime Medicine Inc.	E	21/100	—	—	-35.0%	-2.24%	$950.4M	/prme-vs-mgtx →
ODTX Odyssey Therapeutics Inc.	C-	59/100	—	—	—	+1.48%	$953.0M	/odtx-vs-mgtx →
CGEM Cullinan Therapeutics Inc.	D-	36/100	—	—	-35.0%	-0.71%	$994.3M	/cgem-vs-mgtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001735438

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MeiraGTx Holdings plc (MGTX) reported GAAP revenue of $81.4M (+144.6% vs. FY2024 revenue of $33.3M , and +480.7% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of -$46.4M, and free cash flow of -$50.2M (+54.1% YoY). On the balance sheet, MGTX closed FY2025 with $244.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$81.4M	$0	-$46.4M	-$50.2M	$244.4M	—
FY2024 (FY)	2024-12-31	$33.3M	$0	-$104.5M	-$109.5M	$269.8M	—
FY2023 (FY)	2023-12-31	$14.0M	$0	-$105.4M	-$105.4M	—	—

3. MGTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MGTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, MeiraGTx Holdings plc (NASDAQ: MGTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $9.71 (-0.46% 1D, market cap $932.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MGTX ranks #974 in composite RQD confidence.

How does MGTX compare to GLUE and PRME in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MGTX carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GLUE (Monte Rosa Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $927.4M) and PRME (Prime Medicine Inc.) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $950.4M). Among the 5-stock peer group, MGTX leads on earnings multiple (N/A) while MGTX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MGTX?

Per MGTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001735438), MeiraGTx Holdings plc generated $81.4M in revenue (+144.6% YoY), $0 in net income, and -$50.2M in free cash flow against $244.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MGTX trading relative to its 50-day, 200-day, and 52-week technical levels?

MGTX last traded at $9.71 (-0.46% on volume of 499,196 shares), positioning the stock -17.08% below its 50-day simple moving average ($11.71) and -5.82% below its 200-day simple moving average ($10.31). Across its 52-week range of $6.62 to $15.35, MGTX sits at the 35.4% percentile with a 14-day RSI of 38.3 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($8.62 to $10.80).

MGTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is MGTX's 12-month stock price target?

MeiraGTx Holdings plc (MGTX) carries a 12-month consensus base price target of $8.36 (-13.9% from $9.71), with a bull-case target of $16.12 and a bear-case floor of $6.52.

Is MGTX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates MGTX E (Strong Sell — SELL) with an RQD Confidence score of 27/100.

Direct Sub-Reports: MGTX RQD Cockpit MGTX 12M Forecast MGTX Earnings & Move MGTX Dividends & DRIP MGTX Insiders & 13F MGTX Whale Options MGTX Profit Sankey MGTX News & Why